Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Imprint’s DepotOne needle achieves CE Mark

12.10.2004


Imprint Pharmaceuticals (www.imprintpharma.com) is pleased to announce that its DepotOne needle technology has received its CE Mark and is now cleared for use in Europe. This CE Approval means that the DepotOne needle can be incorporated into clinical studies and existing products with minimal additional regulatory work.



DepotOne is a ‘small’ needle which can replace large needles. It has the penetration characteristics of a small needle with the flow of a large needle. The needle delivers highly viscous materials and will eliminate the need to resort to an unacceptably large needle for subcutaneous or intramuscular injections.

DepotOne is revolutionary as it enables higher doses to be injected. A higher deliverable dose means that new therapeutic products can be developed which have substantially improved product characteristics. The technology is particularly applicable for slow release or depot injectables including pegylated compounds, polymers and highly concentrated protein formulations.


Marketers are fully aware of the significant problems posed by the use of larger needles to the reputation and marketability of an injectable therapeutic product. Thus companies are planning to use DepotOne to reduce the impact of the large needle issue so the positive aspects of their product can be highlighted.

The technology is now being used in a number of clinical trials for high value long acting injectable therapeutics. Kevin Maynard, Business Development Director of Imprint Pharmaceuticals said “DepotOne creates a sea change in the presentation of injectable therapeutics. No longer do patients need to be faced with unacceptably large needles. I believe DepotOne will play a vital role in lowering the resistance to uptake of many of the new biological therapies coming through pharmaceutical companies’ product development lines.”

Imprint Pharmaceuticals Ltd is a centre of expertise in complex injectables. The company supplies tools to enhance the delivery and manufacture of these problematic formulations. Imprint has a range of patented injection devices which enhance the delivery of formulations containing particulates, viscous materials, gels and polymers. In addition, Imprint provides consultancy and patented technologies to enable rapid formulation and scale up of manufacture. Our expertise and patented technologies extend the range of complex injectable products enabling our clients to gain a commercial edge.

Dr Kevin Maynard | alfa
Further information:
http://www.Imprintpharma.com
http://www.oxin.co.uk/

More articles from Health and Medicine:

nachricht 'Icebreaker' protein opens genome for t cell development, Penn researchers find
21.02.2018 | University of Pennsylvania School of Medicine

nachricht Similarities found in cancer initiation in kidney, liver, stomach, pancreas
21.02.2018 | Washington University School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Researchers invent tiny, light-powered wires to modulate brain's electrical signals

21.02.2018 | Life Sciences

The “Holy Grail” of peptide chemistry: Making peptide active agents available orally

21.02.2018 | Life Sciences

Atomic structure of ultrasound material not what anyone expected

21.02.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>